Arvelle Therapeutics GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arvelle Therapeutics GmbH
The France-based firm has assembled a strong syndicate for its sixth generation of 'BioDiscovery' funds, consolidating its position as one of the leading players in life sciences venture capital in Europe.
Heath technology assessment body NICE estimates that around 17,000 patients would be eligible for treatment with Arvelle’s drug.
After strong first-quarter results, SK Biopharmaceuticals expects sales growth to accelerate as the US marketing environment improves and as EU sales of epilepsy drug cenobamate begin.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include three new products, including GlaxoSmithKline's Jemperli (dostarlimab), which is the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer.